ABT
Abbott Laboratories
Stand aside — 200DMA is not rising — regime not clear.
Regime Shift
XLV
sector confirmed
$201,300 CFO$1,100,177 other insiders (2)
3 insider(s)
net purchase ratio +0.07
121d since buy
69
conviction / 100
+6.4 since 21 Aug
73.5
technical / 100
$0–$0
No trade / watch only · Hard gate breached.
Regime clarity15.0
Sponsorship / positioning14.0
Volatility behaviour17.4
Catalyst alignment (insider)9.9
Cross-asset confirmation12.4
Stand aside — hard gate breached
- 200DMA is not rising — regime not clear.
Last
116.64
Add above
127.10
Cut below
87.64
50DMA
99.65
200DMA
105.88
ABT — daily, 14 months
XLV — sector ETF, daily, 14 months
Pillar detail, thesis support and invalidation
Regime clarity
What strengthens the thesis
- price above 200DMA
- 200DMA flat/falling
- 50DMA rising
- higher highs and higher lows
- efficiency ratio 0.38
- OBV 50d slope +0.346 avg-daily-volumes/bar
- no OBV divergence at highs
- OBV fell through last pullback
- last pullback 18.7% deep
- no wide downside expansion bars (30d)
- ATR contracting vs 20d mean
- cluster: 3 distinct insiders buying (1 CFO, 2 Director)
- net purchase ratio +0.07 (3 buying vs 6 selling)
- CFO purchases $201,300 (EVP, CFO)
- 0.0 bps of market cap
- grew the CFO's own position by 3%
- 121 days since the last CFO buy
- closest sector ETF: XLV
- XLV above rising 200DMA (sector-led)
- XLV vs SPY 6m: +0.6 pts
- stock vs XLV RS (3m/6m avg): +4.2 pts
- A confirmed higher high above 127.10 on expanding OBV.
- Pullbacks that hold the rising 50DMA with flat-to-rising OBV.
- XLV extending its own trend while the stock holds relative strength.
- Continued base-building above the reclaimed 200DMA without volatility expansion.
- Loss of the rising 50DMA (99.65) with expanding volatility — reduce.
- Breakdown below the prior structural base (87.64) — exit, no averaging down.
- OBV divergence during a price acceleration — reduce.
- Sector ETF losing its own 200DMA — remove capital regardless of stock behaviour.
- CFO: Boudreau Philip P — EVP, CFO
- 1 CFO purchase(s), $201,300 total; last filed 2026-04-27 17:34:47
- Market cap $203,165,073,408 · 20d avg dollar volume $925,493,206
Roughly balanced — buying is not corroborated.
| Open-market purchases | $1,301,477 |
| Open-market sales | $1,127,827 |
| Sales after option exercise | $0 |
| Distinct buyers / sellers | 3 / 6 |
| Net purchase ratio | +0.07 |
| Net purchase ratio, excl. option-exercise sales | +0.07 |
1 CFO purchase(s) worth $201,300, plus 2 by other insiders worth $1,100,177. Only the CFO purchases score on the size and recency terms.
| Trade date | Insider | Shares | Price | Value | Price now vs buy |
|---|---|---|---|---|---|
| 23 Apr 2026 | Boudreau Philip PCFO | 2,200 | $91.50 | $201,300 | +27.5% |
| 27 Apr 2026 | Starks Daniel JDirector | 10,000 | $92.65 | $926,537 | +25.9% |
| 07 May 2026 | Stratton John GDirector | 2,000 | $86.82 | $173,640 | +34.3% |
8 material events; 0 taken well, 2 badly; last earnings 16 Jul: neutral (+10.7%).
| Session | Filing | Event | Gap | Day | vs SPY | Vol | +5d | Read |
|---|---|---|---|---|---|---|---|---|
| 20 Aug 26 | 8-K | Regulation FD disclosure; Other material event | -0.4% | -0.3% | +0.6% | 0.7x | — | Neutral |
| 28 Jul 26 | 10-Q | Quarterly report | +1.5% | +2.7% | +2.4% | 1.0x | -1.7% | Faded |
| 16 Jul 26 | 8-K · earnings | Results of operations (earnings) | +6.7% | +10.7% | +11.3% | 2.4x | +1.9% | Neutral |
| 29 Apr 26 | 10-Q | Quarterly report | -0.2% | -2.7% | -2.7% | 0.7x | -5.5% | Neutral |
| 27 Apr 26 | 8-K | Director or officer change | +0.5% | +1.8% | +1.7% | 1.3x | -5.7% | Neutral |
| 17 Apr 26 | 8-K | Other material event | +0.2% | +1.4% | +0.2% | 1.3x | -5.9% | Neutral |
| 16 Apr 26 | 8-K · earnings | Results of operations (earnings) | -4.4% | -6.0% | -6.2% | 2.1x | -3.1% | Punished |
| 23 Mar 26 | 8-K | Other material event | +1.5% | -0.6% | -1.6% | 0.7x | -2.8% | Neutral |